Market Intelligence, Clinical Progress, and High-Purity Reagents for Hypertension and Primary Aldosteronism Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CYP11B2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Target Enzyme | CYP11B2 (Aldosterone Synthase) Recombinant Protein Microsomal preparation or purified form, >95% purity, Sequence Verified, Endotoxin <1EU/µg. |
View CYP11B2 Products |
| Selectivity Control | CYP11B1 (11β-Hydroxylase) Recombinant Protein 93% homology counter-screen target, >95% purity, Sequence Verified. |
View CYP11B1 Products |
| Downstream Target | NR3C2 (Mineralocorticoid Receptor) Protein For functional assay validation and competition binding studies. |
View NR3C2 Products |
| Gene Delivery | CYP11B2 ORF / Lentivirus Premade Particles Full-length ORF for stable cell line construction in H295R or HEK293; preserves N-terminal mitochondrial targeting sequence. |
View CYP11B2 Products |
| Validation Antibody | Anti-CYP11B2 Recombinant Antibody Sequence-verified for Western Blot, IHC, and target engagement. |
View CYP11B2 Products |
| Related Target | AGTR1 (Angiotensin II Receptor Type 1) Upstream regulator of renin-angiotensin-aldosterone system (RAAS). |
View AGTR1 Products |
| Related Target | siRNA Set for CYP11B2 Validated for knockdown and specificity verification in cell-based assays. |
View CYP11B2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CYP11B1 vs CYP11B2 Selectivity | Human/Mouse/Rat/Cyno ortholog proteins available (>95% purity); sequence-verified active site homology discrimination. |
| Enzymatic Activity Validation | NADPH-dependent microsomal preparations; Theoretical MW confirmed; Endotoxin <1EU/µg. |
| False Positives / Target Engagement | Validated siRNA for specificity checks; Anti-CYP11B2 antibody for target engagement verification. |
| Native Membrane Conformation | Full-length lentivirus expressed in HEK293 with native mitochondrial import sequence; cell-based enzymatic readouts. |
Live CYP11B2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CYP11B2 therapeutics is intensifying. Major players are shifting from non-selective steroidogenesis inhibitors (e.g., osilodrostat) and mineralocorticoid receptor antagonists to highly selective aldosterone synthase inhibitors (ASIs). Frontrunner baxdrostat (CinCor/AstraZeneca) has advanced into Phase 2/3 trials for resistant hypertension and primary aldosteronism. The next wave of R&D targets fixed-dose combinations with SGLT2 inhibitors, ARNI, and endothelin receptor antagonists to drive deeper cardiovascular and renal protection. A critical bottleneck remains selectivity over CYP11B1 (93% homology); next-generation compounds aim for >100-fold selectivity to avoid cortisol suppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (ASI) | AstraZeneca/CinCor, Novartis, Boehringer Ingelheim | Resistant Hypertension, Primary Aldosteronism | Selectivity panel with high-purity CYP11B2/CYP11B1 proteins |
| siRNA / Antisense | Ionis, Alnylam, Silence Therapeutics | Primary Aldosteronism, Heart Failure | Knockdown validation (siRNA sets, lentivirus controls) |
| PROTACs | Early Academic R&D | Cardiovascular Disease | Degradation assays (lentivirus for cell lines) |
| Combination Therapy | AstraZeneca, Bayer | HFpEF, CKD | Pathway assays (co-expression of CYP11B2 and NR3C2) |
| Steroidogenesis Assay | Academic / Consortium | Adrenal adenoma, Endocrine research | Cell lines with validated ORF expression (lentivirus) |
Genetic Variants of CYP11B2
Known missense variants in CYP11B2 (UniProt P19099) include:
- rs6438 (VAR_014151) – associated with altered enzymatic activity.
- rs6441 (VAR_014152) – linked to hypertension risk modulation.
- CMO-1 deficiency (VAR_018470) – causes complete loss of aldosterone synthase activity, leading to salt-wasting syndrome.
These variants underscore the need for reliable recombinant proteins and antibodies to study structure–function relationships and to develop genotype-informed therapies.